NCT Number: NCT00034268
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
The purposes of this study are to determine:
1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2. The safety of LY900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combination of these three drugs. 3. Whether LY900003 plus gemcitabine and cisplatin can make your tumor smaller or disappear, and for how long, compared with gemcitabine and cisplatin alone.
It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate LY900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed.
LY900003 may not add any benefit to gemcitabine plus cisplatin.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Mendoza, Mendoza Province, Argentina
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Stage IIIB or IV non-small lung cancer
- Able to visit the doctor's office
- At least 18 years of age
- Adequate kidney, adrenal, and liver function
Exclusion criteria
- Prior chemotherapy or biologic therapy for NSCLC
- Central nervous system tumors
- Pregnant or breastfeeding
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Important dates
- Study start
- 2002
- First posted
- Apr 25, 2002
- Registry last updated
- Jul 19, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
NCT04838548
Bronchial Neoplasms, Carcinoma, Bronchogenic
Beijing, Beijing Municipality, China
View Trial DetailsStudy of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423
Bronchial Neoplasms, Carcinoma, Bronchogenic
Long Beach, California, United States
View Trial DetailsTesting of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
NCT01652469
Bronchial Neoplasms, Carcinoma, Bronchogenic
Vienna, Austria
View Trial DetailsA Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
NCT05241834
Bronchial Neoplasms, Carcinoma, Bronchogenic
Los Angeles, California, United States
View Trial Details